Scientists explain how cell death caused from this protein could lead to drug treatments to prevent the inflammatory, cell-killing response of septic shock.
St. Jude Children’s Research Hospital are testing a game-changing technique for predicting infection in patients with weakened immune systems.
Elizabeth Fox, M.D. will oversee clinical trials research administration and strategy and serve as the associate director for clinical research.
A study from
St. Jude Children’s Research Hospital sheds light on the mechanisms governing feeding behavior in fruit flies and how skeletal muscle communicates energy needs to the brain.
Read about a molecule that researchers are targeting in hopes of improving cancer immunotherapy, including CAR-T cell therapy, against solid tumors as well as leukemia.
Findings presented by a
St. Jude Children’s Research Hospital investigator showcase the power and potential of combining genomic and transcriptomic data.
St. Jude Children’s Research Hospital will present their work at the 61st annual meeting of the American Society of Hematology.
Researchers know that different biology underlies CLL and ALL. However, there may be a link between the two diseases.
Nearly 20 scientists from
St. Jude Children's Research Hospital named Highly Cited Researchers for 2019 by the Web of Science group.
Gene therapy developed by the late Brian Sorrentino honored by Smithsonian Magazine.
Dr. Justin Baker is one of six finalists for the National Compassionate Caregiver of the Year Award.
Research co-led by a
St. Jude investigator and researchers from Columbia University and the New York State Psychiatric Institute reveals the mechanics of how some transporter proteins function with stunning specificity.
An International collaboration has identified therapy-induced, drug-resistance mutations in children with acute lymphoblastic leukemia who relapse.
St. Jude have announced results of the Total Therapy Study 16 clinical trial, which tested strategies for lowering the rate of relapse of acute lymphoblastic leukemia in children from 2007–2017.
St. Jude researchers have discovered two enzymes that may have a crucial role in treating autoimmune disorders and certain cancers.
St. Jude Children’s Research Hospital online portal into pediatric cancer survivorship data debuts at the American Society of Human Genetics annual meeting.
St. Jude and the IAEA partner to raise awareness of childhood cancers, increase professional training, and support research in pediatric radiation oncology.
Douglas R. Green, Ph.D., is one of four recipients of the 2019 Wilbur Lucius Cross Medal for Alumni Achievement from the Yale Graduate School.
St. Jude launches a Paws at Play hospital dog program to help pediatric patients cope with the challenges of treatment and hospitalization.
How do stressed cells choose between survival or death? Evidence suggests the molecule DDX3X plays a role and offers a possible strategy for controlling chronic inflammation.
New NMR will allow
St. Jude researchers to study proteins, DNA, RNA and other biomolecules to better understand catastrophic diseases.
Scientists have used a 3D genome to improve understanding of gene regulation during development and disease. Read the latest.
A fresh take on the common blood disorder, b-thalassemia leads researchers to a novel therapy using rapamycin that is ready for clinical trial.
Aseem Ansari, Ph.D., will join
St. Jude Children’s Research Hospital as chair of the Department of Chemical Biology and Therapeutics.
A new study has for the first time looked at the global burden of pediatric cancer through the lens of years of affected and lost life.
St. Jude Children’s Research Hospital has found that prominent cancer risk gene BRCA2 can increase risk of non-Hodgkin lymphoma in children and adolescents.
St. Jude Children’s Research Hospital and Massachusetts General Hospital digs into the cells of origin for key medulloblastoma subtypes.
St. Jude Children’s Research Hospital scientists discovered an association between a mutation that causes a lysosomal storage disorder and fibrotic conditions, including idiopathic pulmonary fibrosis
St. Jude Children’s Research Hospital scientists reveal a crystal structure that illustrates a mechanism that powers and possibly starts DNA replication.
A new pathway called LANDO may protect against neurodegeneration in Alzheimer's disease. Learn about how inhibiting this pathway may positively affect treatment.
St. Jude scientists found that despite having few mutations, pediatric acute lymphoblastic leukemia does not escape immune detection.
This study provided the first detailed genomic and epigenomic map of the IGH-DUX4 rearrangement and suggested the principle a model for the IGH-DUX4 contribution to B-ALL.
St. Jude Children’s Research Hospital is ranked as the No. 2 pediatric cancer hospital on U.S. News & World Report’s 13th Annual “Best Children’s Hospitals” list.
The platform is the first to release prospective, comprehensive clinical whole-genome sequencing data directly from the clinic to the cloud.
Researchers found about 70 bacterial proteins that played an important role in transmission, and suggest combination vaccines to block and prevent invasive disease.
The work of
St. Jude Children’s Research Hospital will be on display at the 55th annual meeting of the American Society of Clinical Oncology in Chicago
St. Jude chosen to lead an international effort to define how flu infections early in life shape the immune response to virus.
Research shows how flu and respiratory bacteria work together to gain a foothold in the respiratory tract, and the first report of flu sticking to surface of respiratory bacteria.
St. Jude experts present pediatric oncology and survivorship research at the annual meeting of the American Society of Clinical Oncology.
The 2019 Gertrude B. Elion Cancer Research Award supports researchers to advance research focused on the cause, diagnosis, treatment or prevention of cancer.
In the first study to identify the key cognitive components that lead to reading problems, researchers identify potential interventions to help survivors become better readers.
Roussel’s appointment marks a historic moment in National Academy of Sciences history with a record number of women elected to the academy.
Unchecked cell division leads to cancer. The fluctuations in the intrinsically disordered protein p27 helps keep the process on track.
The findings suggest that patrolling monocytes may drive glomerulonephritis, inflammation of the kidneys. Exploring these mechanisms may lead to new drug targets.
The new role will help guide precision medicine and preclinical efforts as well as other strategic research initiatives.
Novel combination gene therapy pioneered at
St. Jude cures "bubble boy" disease and provides template for treating other genetic disorders. Read about the landmark study.
Collaboration will improve the understanding of how advanced technologies, such as gene therapy for hemophilia B, can move rapidly to countries with limited resources.
Toxic DPRs disrupt cell function in ALS, much like uninvited dinner party guests, and displace binding partners that help maintain normal nucleolus and ribosome assembly.
Enzymes ULK1 and ULK2 play a key role in breaking down cell structures called stress granules, whose persistence leads to toxic buildup of proteins that kill muscle and brain cells
The recognition was earned for sharing several decades worth of genetic cancer data and a five-year collaboration with World Health Organization.
Explore research and resources by
St. Jude at the 2019 Annual Meeting of the American Association for Cancer Research (AACR) in Atlanta.
This investigation draws on whole genome sequencing and other data gathered longitudinally through the
St. Jude Lifetime Cohort (SJLIFE) study.
The study identified a novel variant of the USP7 gene as playing a role in increasing the risk of developing T-ALL. The inherited genetic variant is linked to lower expression of USP7.
Research ranges on a variety of topics such as survivorship, clinical genomics, deep sequencing, disease models and the biology of pediatric cancers.
Genomic analysis reveals the biology of acute erythroid leukemia, a rare cancer with few survivors
St. Jude Cancer Control and Survivorship Program is a multidisciplinary research program which strives to improve the quality of life of individuals surviving childhood cancer.
The agreement reflects the
St. Jude commitment to transform pediatric cancer care in low- to moderate-income nations that are home to 90 percent of childhood cancer patients.
Check out what happens when math and biology combine to tackle error rates in next-generation DNA sequencing. The answer is good news for cancer patients.
Downing will discuss our understanding of the molecular landscape of childhood cancer, which can benefit cancer patients of all ages and raise global cancer cure rates.
Comprehensive clinical genomic testing proves its worth; leads to discovery of a mutation that drives the most common childhood melanoma.
Cooperative clinical trial gives immediate postoperative radiation for children under age 3 with ependymoma, illustrates effectiveness of postoperative radiation.
Progress reported on understanding why Hispanic children are more likely to develop acute lymphoblastic leukemia and to die of the disease.
The institution is the highest-ranked Memphis-based organization; for nearly a decade, Fortune has recognized the hospital’s commitment to employee
St. Jude Children’s Research Hospital announced it has been named a recipient of Microsoft Corp.’s 2019 Health Innovation Awards.
Researchers developed a method for customizing and reducing drug interaction alerts in electronic health records for pediatric cancer patients.
New program will integrate traditional training and experiential learning at
St. Jude campus and partner site.
The study reports how two unexpected partners, the proteins UTX and 53BP1, link up to regulate a brain development program comprising hundreds of genes.
Survey results should help health system leaders and patient safety experts dedicate resources to improve safety and clinical outcomes in pediatric health care.
Children with hypodiploid acute lymphoblastic leukemia fare better when minimal residual disease is used to guide treatment.
Research led by
St. Jude Children's Research Hospital means more than 90 percent of the most common cases of childhood cancer can now be classified by subtype, an advance likely to fuel precision medicine.